Prevention & lipidsRandomised controlled trial

Effects of Combining Coronary Calcium Score With Treatment on Plaque Progression in Familial Coronary Artery Disease

JAMAPublished

  • Randomised controlled trial
  • open-blinded end point
  • prospective
  • 7 hospitals across Australia

Authors' conclusion

The combination of CAC score with a primary prevention strategy in intermediate-risk patients with a family history of CAD was associated with reduction of atherogenic lipids and slower plaque progression compared with usual care.

Study context

Population
Asymptomatic intermediate-risk adults aged 40–70 y with a family history of premature coronary artery disease (CAD) and coronary artery calcium (CAC) score >0 but <400
Participants
365 adults
Comparison
CAC score-informed prevention vs usual care
  • CAC score-informedn = 179
  • Usual caren = 186reference
Primary endpoint
Total plaque volume progression on coronary computed tomography angiography (CCTA) (core laboratory)
Follow-up
3 years

Primary result

As reported in the abstract

Total plaque volume progression

P = 0.009

Further findings

Noncalcified plaque volume progression · 3 years

P = 0.002

Mean, mm3

OutcomeCAC score-informedUsual careP value
Fibrofatty and necrotic core plaque volume progression · 3 years−0.8 (SD 12.6)4.5 (SD 25.8)P = 0.02

Total and LDL cholesterol change; pooled cohort equation risk · 3 years

Sustained reduction in total cholesterol with CAC score-informed vs usual care (mean [SD])
−3 [31] mg/dL vs −56 [38] mg/dL; P < .001
Sustained reduction in LDL cholesterol with CAC score-informed vs usual care (mean [SD])
−2 [31] vs −51 [36] mg/dL; P < .001
Reduction in pooled cohort equation risk (mean [SD])
2.1% [2.9%] vs 0.5% [2.9%]; P < .001

Original publication

Effects of Combining Coronary Calcium Score With Treatment on Plaque Progression in Familial Coronary Artery Disease. JAMA. Published 22 April 2025. doi:10.1001/jama.2025.0584

Summarised from the published abstract; every number is checked against it